Serum CTGF in Chronic Plantar Fasciitis
Not yet recruitingNCT07785453
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This observational study aims to evaluate serum Connective Tissue Growth Factor (CTGF/CCN2) levels in patients with chronic plantar fasciitis compared with asymptomatic controls. The study will also assess the associations between serum CTGF levels and clinical and ultrasonographic characteristics of chronic plantar fasciitis.
Study details
- Official title
- Association of Serum Connective Tissue Growth Factor (CTGF/CCN2) Levels With Pain and Functional Status in Patients With Chronic Plantar Fasciitis
- Conditions
- Sponsor
- Kanuni Sultan Suleyman Training and Research Hospital
- Start date
- 2026-08-30
- Primary completion
- 2026-10-30
- Sex
- All
- Age range
- from 18 Years to 65 Years
- Healthy volunteers
- true
- Results posted
- No results posted in this snapshot
- Total sites listed
- 0
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Age 18-65 years. * Written informed consent. * For the patient group: chronic plantar heel pain for at least 3 months, pain during the first steps in the morning or after prolonged rest, tenderness over the medial calcaneal tubercle, and clinical and ultrasonographic findings consistent with chronic plantar fasciitis. * For the control group: asymptomatic individuals without a previous diagnosis or clinical and ultrasonographic findings of plantar fasciitis. Exclusion Criteria: * Tarsal tunnel syndrome, calcaneal stress fracture, plantar fascia rupture, Achilles tendinopathy, heel fat pad syndrome, plantar fibromatosis, or other foot conditions causing plantar heel pain. * Diabetes mellitus. * Inflammatory rheumatic diseases or gout. * Chronic kidney or liver disease. * Malignancy. * Active infection or autoimmune disease * Pregnancy. * Previous foot or ankle surgery. * Corticosteroid injection, platelet-rich plasma (PRP), prolotherapy, extracorporeal shock wave therapy (ESWT), or other interventional treatment to the affected heel within the previous 3 months. * Serious systemic conditions that may affect serum CTGF/CCN2 levels.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT07785453